Value Sense
SLN
Silence Therapeutics plc (SLN)
Last Price$4.3(4.0%)
Market Cap$211.4B
LTM EPS
(£0.7)
-36.0% YOY growth
NTM EPS
(£0.5)
-29.3% YOY growth
Current P/E
(2,826.5x) LTM
(5,963.3x) NTM
52w high P/E
(1.1x) LTM
(2.3x) NTM
52w low P/E
(2,826.5x) LTM
(5,963.3x) NTM
10Y avg P/E
(17.2x) LTM
(29.5x) NTM
SLN
is 99.8% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

SLN Peter Lynch Chart

Crunching data... Almost there!

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

Explore more intrinsic value tools hub for SLN

Earnings growth model
Peter Lynch Fair Value
Earnings Power Value
Discount rate
Ben Graham Fair Value
Reverse DCF
Relative Value
Intrinsic Value
DCF value calculator
Margin of safety

FAQ

What is Silence Therapeutics plc earnings per share (EPS)?

Silence Therapeutics plc earnings per share (EPS) for the twelve months ending Mar 03, 2025 was (£0.7), a (36.0%) increase year-over-year.

What is Silence Therapeutics plc Price to Earnings (P/E) ratio?

As of Mar 03, 2025, Silence Therapeutics plc's P/E ratio is (2,826.5x). This is calculated by dividing the current share price of $4.3 by the Earnings per Share (EPS) for the trailing twelve months, which is (£0.7). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

Is Silence Therapeutics plc overvalued or undervalued?

Silence Therapeutics plc is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $0.0, compared to a market price of around $4.3. This suggests a potential overvaluation of 99.8%.